title: Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide.
abstract: BACKGROUND
  Standard treatment of glioblastoma multiforme consists of postoperative radiochemotherapy with temozolomide, followed by a 6-month chemotherapy. Serious hematologic complications are rarely reported.
  
  
  RESULTS
  The authors present the case of a 61-year-old female patient with glioblastoma multiforme treated with external-beam radiation therapy and concomitant temozolomide. After completion of treatment, the patient developed symptoms of serious aplastic anemia that eventually led to death due to prolonged neutro- and thrombocytopenia followed by infectious complications.
  
  
  CONCLUSIONS
  Lethal complications following temozolomide are, per se, extremely rare, however, a total of four other cases of aplastic anemia have been reported in the literature so far.
authors.affiliation: Department of Clinical Oncology and Radiotherapy, Charles University Hospital and Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic. kopecjin@fnhk.cz
authors.forename: Jindrich
authors.initials: J
authors.lastname: Kopecký
authors.forename: Peter
authors.initials: P
authors.lastname: Priester
authors.forename: Ladislav
authors.initials: L
authors.lastname: Slovácek
authors.forename: Jirí
authors.initials: J
authors.lastname: Petera
authors.forename: Otakar
authors.initials: O
authors.lastname: Kopecký
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Macingova
mesh_terms: D000741:Anemia, Aplastic / Q000139:chemically induced* / Q000401:mortality*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use / Q000633:toxicity*; D001772:Blood Cell Count; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D002423:Cause of Death; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D019583:Dose Fractionation, Radiation; D005260:Female; D005625:Frontal Lobe; D005909:Glioblastoma / Q000188:drug therapy* / Q000532:radiotherapy*; D006474:Hemorrhagic Disorders / Q000139:chemically induced / Q000401:mortality; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D010296:Parietal Lobe; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide
references.citation: Strahlenther Onkol. 2009 Aug;185(8):524-9
references.pmid: 19652936
references.citation: N Engl J Med. 2005 Mar 10;352(10):997-1003
references.pmid: 15758010
references.citation: Cancer Chemother Pharmacol. 2009 Sep;64(4):647-55
references.pmid: 19543728
references.citation: Strahlenther Onkol. 2008 Nov;184(11):572-9
references.pmid: 19016015
references.citation: J Neurooncol. 2010 Jan;96(2):249-57
references.pmid: 19582373
references.citation: J Neurol. 2002 Aug;249(8):955-60
references.pmid: 12195437
references.citation: Neuro Oncol. 2007 Jan;9(1):47-52
references.pmid: 17108062
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: South Med J. 2009 Sep;102(9):974-6
references.pmid: 19668033
references.citation: Lancet Oncol. 2006 May;7(5):436-8
references.pmid: 16648049
references.citation: Strahlenther Onkol. 2005 Mar;181(3):157-63
references.pmid: 15756519
references.citation: Strahlenther Onkol. 2009 Apr;185(4):235-40
references.pmid: 19370426
references.citation: Strahlenther Onkol. 2009 Nov;185(11):743-50
references.pmid: 19899008
references.citation: J Neurooncol. 2007 Nov;85(2):229-30
references.pmid: 17530175
references.citation: Lancet Neurol. 2004 Mar;3(3):159-68
references.pmid: 14980531